Spots Global Cancer Trial Database for Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

Official Title: Multi-Center, Randomized, Open, Phase II Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy

Study ID: NCT01923545

Conditions

Chemotherapy Induced Neutropenia

Interventions

PEG-G-CSF

G-CSF

Study Description

Brief Summary: This study is to examine which dose of DA-3031(PEG-G-CSF) has similar efficacy and safety compared to daily G-CSF in chemotherapy-induced neutropenia.

Detailed Description: Eligible subjects are randomly assigned to receive once-per-cycle DA-3031(PEG-G-CSF) or daily G-CSF(up to 10 days). This study is conducted for 1 cycles of chemotherapy.